Cargando…

Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)

Trimodality therapy consisting of high dose rate (HDR) brachytherapy combined with external beam radiation therapy (EBRT), neoadjuvant hormonal therapy (NHT) and adjuvant hormonal therapy (AHT) has been used to treat localized high-risk prostate cancer. In this study, an analysis of patients receivi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aoki, Manabu, Miki, Kenta, Kido, Masahito, Sasaki, Hiroshi, Nakamura, Wataru, Kijima, Yoshikazu, Kobayashi, Masao, Egawa, Shin, Kanehira, Chihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014157/
https://www.ncbi.nlm.nih.gov/pubmed/24351458
http://dx.doi.org/10.1093/jrr/rrt134
_version_ 1782315144725921792
author Aoki, Manabu
Miki, Kenta
Kido, Masahito
Sasaki, Hiroshi
Nakamura, Wataru
Kijima, Yoshikazu
Kobayashi, Masao
Egawa, Shin
Kanehira, Chihiro
author_facet Aoki, Manabu
Miki, Kenta
Kido, Masahito
Sasaki, Hiroshi
Nakamura, Wataru
Kijima, Yoshikazu
Kobayashi, Masao
Egawa, Shin
Kanehira, Chihiro
author_sort Aoki, Manabu
collection PubMed
description Trimodality therapy consisting of high dose rate (HDR) brachytherapy combined with external beam radiation therapy (EBRT), neoadjuvant hormonal therapy (NHT) and adjuvant hormonal therapy (AHT) has been used to treat localized high-risk prostate cancer. In this study, an analysis of patients receiving the trimodality therapy was performed to identify prognostic factors of biochemical relapse-free survival (bRFS). Between May 2005 and November 2008, 123 high-risk prostate cancer patients (D'Amico classification) were treated with NHT prior to HDR brachytherapy combined with hypofractionated EBRT. Among these patients, 121 had completed AHT. The patients were assigned by time to be treated with a low-dose or high-dose arm of HDR brachytherapy with subsequent hypofractionated 3D conformal radiation therapy (3D-CRT). Multivariate analysis was used to determine prognostic factors for bRFS. With a median follow-up of 60 months, the 5-year bRFS for all patients was 84.3% (high-dose arm, 92.9%; low-dose arm, 72.4%, P = 0.047). bRFS in the pre-HDR PSA ≤ 0.1 ng/ml subgroup was significantly improved compared with that in the pre-HDR PSA > 0.1 ng/ml subgroup (88.3% vs 68.2%, P = 0.034). On multivariate analysis, dose of HDR (P = 0.045, HR = 0.25, 95% CI = 0.038–0.97) and pre-HDR PSA level (P = 0.02 HR = 3.2, 95% CI = 1.18–10.16) were significant prognostic factors predicting bRFS. In high-risk prostate cancer patients treated with the trimodality therapy, the dose of HDR and pre-HDR PSA were significant prognostic factors. The pre-HDR PSA ≤ 0.1 subgroup had significantly improved bRFS. Further studies are needed to confirm the relevance of pre-HDR PSA in trimodality therapy.
format Online
Article
Text
id pubmed-4014157
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-40141572014-05-12 Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy) Aoki, Manabu Miki, Kenta Kido, Masahito Sasaki, Hiroshi Nakamura, Wataru Kijima, Yoshikazu Kobayashi, Masao Egawa, Shin Kanehira, Chihiro J Radiat Res Oncology Trimodality therapy consisting of high dose rate (HDR) brachytherapy combined with external beam radiation therapy (EBRT), neoadjuvant hormonal therapy (NHT) and adjuvant hormonal therapy (AHT) has been used to treat localized high-risk prostate cancer. In this study, an analysis of patients receiving the trimodality therapy was performed to identify prognostic factors of biochemical relapse-free survival (bRFS). Between May 2005 and November 2008, 123 high-risk prostate cancer patients (D'Amico classification) were treated with NHT prior to HDR brachytherapy combined with hypofractionated EBRT. Among these patients, 121 had completed AHT. The patients were assigned by time to be treated with a low-dose or high-dose arm of HDR brachytherapy with subsequent hypofractionated 3D conformal radiation therapy (3D-CRT). Multivariate analysis was used to determine prognostic factors for bRFS. With a median follow-up of 60 months, the 5-year bRFS for all patients was 84.3% (high-dose arm, 92.9%; low-dose arm, 72.4%, P = 0.047). bRFS in the pre-HDR PSA ≤ 0.1 ng/ml subgroup was significantly improved compared with that in the pre-HDR PSA > 0.1 ng/ml subgroup (88.3% vs 68.2%, P = 0.034). On multivariate analysis, dose of HDR (P = 0.045, HR = 0.25, 95% CI = 0.038–0.97) and pre-HDR PSA level (P = 0.02 HR = 3.2, 95% CI = 1.18–10.16) were significant prognostic factors predicting bRFS. In high-risk prostate cancer patients treated with the trimodality therapy, the dose of HDR and pre-HDR PSA were significant prognostic factors. The pre-HDR PSA ≤ 0.1 subgroup had significantly improved bRFS. Further studies are needed to confirm the relevance of pre-HDR PSA in trimodality therapy. Oxford University Press 2014-05 2013-12-17 /pmc/articles/PMC4014157/ /pubmed/24351458 http://dx.doi.org/10.1093/jrr/rrt134 Text en © The Author 2013. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Radiation Oncology. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Oncology
Aoki, Manabu
Miki, Kenta
Kido, Masahito
Sasaki, Hiroshi
Nakamura, Wataru
Kijima, Yoshikazu
Kobayashi, Masao
Egawa, Shin
Kanehira, Chihiro
Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title_full Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title_fullStr Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title_full_unstemmed Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title_short Analysis of prognostic factors in localized high-risk prostate cancer patients treated with HDR brachytherapy, hypofractionated 3D-CRT and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
title_sort analysis of prognostic factors in localized high-risk prostate cancer patients treated with hdr brachytherapy, hypofractionated 3d-crt and neoadjuvant/adjuvant androgen deprivation therapy (trimodality therapy)
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014157/
https://www.ncbi.nlm.nih.gov/pubmed/24351458
http://dx.doi.org/10.1093/jrr/rrt134
work_keys_str_mv AT aokimanabu analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT mikikenta analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT kidomasahito analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT sasakihiroshi analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT nakamurawataru analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT kijimayoshikazu analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT kobayashimasao analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT egawashin analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy
AT kanehirachihiro analysisofprognosticfactorsinlocalizedhighriskprostatecancerpatientstreatedwithhdrbrachytherapyhypofractionated3dcrtandneoadjuvantadjuvantandrogendeprivationtherapytrimodalitytherapy